PREVEnt Trial

Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome”

Aytu BioPharma, Inc. will be sponsoring an upcoming clinical trial to evaluate the effectiveness of AR101 (enzastaurin) in preventing cardiac or arterial events in patients with:

Vascular Ehlers-Danlos Syndrome (VEDS)

Confirmed COL3A1 gene mutation

To find out more about this trial, simply fill out the form below.

Share this study: